5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Sell
30
ATAI Quote, Financials, Valuation and Earnings
Last price:
$1.42
Seasonality move
:
-9.43%
Day range:
$1.29 - $1.44
52-week range:
$1.03 - $2.57
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
737.67x
P/B ratio:
2.39x
Volume:
1.4M
Avg. volume:
1.6M
1-year change:
-30.35%
Market cap:
$277.6M
Revenue:
$308K
EPS (TTM):
-$0.93
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
-- | -$0.18 | 1288.89% | -5.88% | $8.00 |
|
AFMD
Affimed NV
|
$1.3M | -$0.57 | 675.99% | -58.88% | $12.97 |
|
BNTX
BioNTech SE
|
$183.4M | -$2.66 | 11.73% | -20.7% | $136.58 |
|
FMS
Fresenius Medical Care AG
|
$5.4B | $0.43 | 12.44% | 40.55% | $26.67 |
|
IFRX
InflaRx NV
|
$36.3K | -$0.20 | -5.26% | -0.05% | $9.56 |
|
IMTX
Immatics NV
|
$15.4M | -$0.33 | -54.61% | -795.32% | $15.30 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
$1.40 | $8.00 | $277.6M | -- | $0.00 | 0% | 737.67x |
|
AFMD
Affimed NV
|
$0.70 | $12.97 | $11.5M | -- | $0.00 | 0% | 11.33x |
|
BNTX
BioNTech SE
|
$94.78 | $136.58 | $22.8B | 191.55x | $0.00 | 0% | 7.68x |
|
FMS
Fresenius Medical Care AG
|
$28.07 | $26.67 | $16.5B | 24.58x | $0.64 | 2.29% | 0.79x |
|
IFRX
InflaRx NV
|
$1.58 | $9.56 | $106.1M | -- | $0.00 | 0% | 512.31x |
|
IMTX
Immatics NV
|
$4.34 | $15.30 | $527.5M | 39.14x | $0.00 | 0% | 2.81x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
16.81% | 3.382 | 10.51% | 2.55x |
|
AFMD
Affimed NV
|
31.93% | 1.600 | 16.35% | 1.76x |
|
BNTX
BioNTech SE
|
1.53% | 1.910 | 1.45% | 9.86x |
|
FMS
Fresenius Medical Care AG
|
32.23% | 0.593 | 46.71% | 0.93x |
|
IFRX
InflaRx NV
|
-- | 4.290 | -- | 3.85x |
|
IMTX
Immatics NV
|
-- | 0.533 | -- | 8.99x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
-- | -$30.4M | -74.54% | -83.02% | 764640% | -$24.4M |
|
AFMD
Affimed NV
|
-- | -$15.7M | -127.62% | -158.94% | -9594.22% | -$13.2M |
|
BNTX
BioNTech SE
|
$104.2M | -$562M | -3.86% | -3.91% | -225.11% | -$1.5B |
|
FMS
Fresenius Medical Care AG
|
$1.2B | $401.7M | 3% | 4.05% | 7.1% | $18M |
|
IFRX
InflaRx NV
|
-$3M | -$10.4M | -56.78% | -56.78% | 1207051.66% | -$12.3M |
|
IMTX
Immatics NV
|
-- | $962.6K | 3.71% | 3.71% | 77.34% | -$63.2M |
ATAI Life Sciences NV vs. Competitors
-
Which has Higher Returns ATAI or AFMD?
Affimed NV has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of -9767.12%. ATAI Life Sciences NV's return on equity of -83.02% beat Affimed NV's return on equity of -158.94%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M AFMDAffimed NV-- -$1.03 $28.2M -
What do Analysts Say About ATAI or AFMD?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand Affimed NV has an analysts' consensus of $12.97 which suggests that it could grow by 1753.37%. Given that Affimed NV has higher upside potential than ATAI Life Sciences NV, analysts believe Affimed NV is more attractive than ATAI Life Sciences NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 AFMDAffimed NV4 0 0 -
Is ATAI or AFMD More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Affimed NV has a beta of 2.071, suggesting its more volatile than the S&P 500 by 107.149%.
-
Which is a Better Dividend Stock ATAI or AFMD?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Affimed NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Affimed NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or AFMD?
ATAI Life Sciences NV quarterly revenues are -$5K, which are smaller than Affimed NV quarterly revenues of $170.5K. ATAI Life Sciences NV's net income of -$39M is lower than Affimed NV's net income of -$16.7M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Affimed NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus 11.33x for Affimed NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M AFMDAffimed NV11.33x -- $170.5K -$16.7M
-
Which has Higher Returns ATAI or BNTX?
BioNTech SE has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of -227.46%. ATAI Life Sciences NV's return on equity of -83.02% beat BioNTech SE's return on equity of -3.91%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M BNTXBioNTech SE54.16% -$1.82 $20.8B -
What do Analysts Say About ATAI or BNTX?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand BioNTech SE has an analysts' consensus of $136.58 which suggests that it could grow by 44.1%. Given that ATAI Life Sciences NV has higher upside potential than BioNTech SE, analysts believe ATAI Life Sciences NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 BNTXBioNTech SE13 4 0 -
Is ATAI or BNTX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.347, suggesting its more volatile than the S&P 500 by 34.675%.
-
Which is a Better Dividend Stock ATAI or BNTX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or BNTX?
ATAI Life Sciences NV quarterly revenues are -$5K, which are smaller than BioNTech SE quarterly revenues of $192.3M. ATAI Life Sciences NV's net income of -$39M is higher than BioNTech SE's net income of -$437.5M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus 7.68x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M BNTXBioNTech SE7.68x 191.55x $192.3M -$437.5M
-
Which has Higher Returns ATAI or FMS?
Fresenius Medical Care AG has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of 3.1%. ATAI Life Sciences NV's return on equity of -83.02% beat Fresenius Medical Care AG's return on equity of 4.05%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M FMSFresenius Medical Care AG24.26% $0.27 $24.2B -
What do Analysts Say About ATAI or FMS?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand Fresenius Medical Care AG has an analysts' consensus of $26.67 which suggests that it could fall by -4.98%. Given that ATAI Life Sciences NV has higher upside potential than Fresenius Medical Care AG, analysts believe ATAI Life Sciences NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 FMSFresenius Medical Care AG1 4 1 -
Is ATAI or FMS More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fresenius Medical Care AG has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.616%.
-
Which is a Better Dividend Stock ATAI or FMS?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fresenius Medical Care AG offers a yield of 2.29% to investors and pays a quarterly dividend of $0.64 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Fresenius Medical Care AG pays out 64.91% of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ATAI or FMS?
ATAI Life Sciences NV quarterly revenues are -$5K, which are smaller than Fresenius Medical Care AG quarterly revenues of $5.1B. ATAI Life Sciences NV's net income of -$39M is lower than Fresenius Medical Care AG's net income of $159.1M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Fresenius Medical Care AG's PE ratio is 24.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus 0.79x for Fresenius Medical Care AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M FMSFresenius Medical Care AG0.79x 24.58x $5.1B $159.1M
-
Which has Higher Returns ATAI or IFRX?
InflaRx NV has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of -14092.9%. ATAI Life Sciences NV's return on equity of -83.02% beat InflaRx NV's return on equity of -56.78%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M IFRXInflaRx NV-5376.61% -$0.09 $63.9M -
What do Analysts Say About ATAI or IFRX?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand InflaRx NV has an analysts' consensus of $9.56 which suggests that it could grow by 505.22%. Given that InflaRx NV has higher upside potential than ATAI Life Sciences NV, analysts believe InflaRx NV is more attractive than ATAI Life Sciences NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 IFRXInflaRx NV5 1 0 -
Is ATAI or IFRX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.572, suggesting its more volatile than the S&P 500 by 57.18%.
-
Which is a Better Dividend Stock ATAI or IFRX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or IFRX?
ATAI Life Sciences NV quarterly revenues are -$5K, which are smaller than InflaRx NV quarterly revenues of -$450. ATAI Life Sciences NV's net income of -$39M is lower than InflaRx NV's net income of -$5.4M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus 512.31x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M IFRXInflaRx NV512.31x -- -$450 -$5.4M
-
Which has Higher Returns ATAI or IMTX?
Immatics NV has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of 79.75%. ATAI Life Sciences NV's return on equity of -83.02% beat Immatics NV's return on equity of 3.71%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M IMTXImmatics NV-- $0.46 $598.2M -
What do Analysts Say About ATAI or IMTX?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand Immatics NV has an analysts' consensus of $15.30 which suggests that it could grow by 252.54%. Given that ATAI Life Sciences NV has higher upside potential than Immatics NV, analysts believe ATAI Life Sciences NV is more attractive than Immatics NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 IMTXImmatics NV6 0 0 -
Is ATAI or IMTX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.706%.
-
Which is a Better Dividend Stock ATAI or IMTX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or IMTX?
ATAI Life Sciences NV quarterly revenues are -$5K, which are smaller than Immatics NV quarterly revenues of $60M. ATAI Life Sciences NV's net income of -$39M is lower than Immatics NV's net income of $47.8M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Immatics NV's PE ratio is 39.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus 2.81x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M IMTXImmatics NV2.81x 39.14x $60M $47.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
99
DAVE alert for May 9
Dave [DAVE] is up 8.4% over the past day.
Buy
52
QDEL alert for May 9
QuidelOrtho [QDEL] is up 0.47% over the past day.
Buy
61
TPC alert for May 9
Tutor Perini [TPC] is up 7.3% over the past day.
